Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways

2018123 citationsJournal Articlegold Open Access

Authors

This study provides evidence of the cardioprotective activity of Pris which is related to the modulation of Nrf2 and MAPK/NF-kB signaling pathways.

Good health and well-being

Published in: Cancer Management and Research

Volume Volume 11, pp. 47-61

Field-Weighted Citation Impact: 8.02